DiaMedica Therapeutics, Inc. (DMAC) – What Are Researchers Saying About This Stock?

Shares of DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) have earned a consensus rating of “Moderate Buy” from the five brokerages that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $12.00.

Several research firms have recently commented on DMAC. Weiss Ratings reiterated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Thursday, October 15th. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of DiaMedica Therapeutics in a report on Tuesday, August 11th.

Hedge Funds Weigh In On DiaMedica Therapeutics

A number of large investors have recently bought and sold shares of the stock. Squarepoint Ops LLC bought a new stake in DiaMedica Therapeutics in the second quarter valued at approximately $1,023,000. Bank of New York Mellon Corp purchased a new stake in shares of DiaMedica Therapeutics during the second quarter valued at approximately $829,000. Sei Investments Co. grew its holdings in shares of DiaMedica Therapeutics by 100.0% in the first quarter. Sei Investments Co. now owns 111,320 shares of the company’s stock worth $754,000 after purchasing an additional 55,660 shares during the last quarter. Renaissance Technologies LLC bought a new position in shares of DiaMedica Therapeutics in the first quarter worth approximately $356,000. Finally, Bank of America Corp DE grew its holdings in shares of DiaMedica Therapeutics by 62.5% in the first quarter. Bank of America Corp DE now owns 42,768 shares of the company’s stock worth $290,000 after purchasing an additional 16,446 shares during the last quarter. 10.12% of the stock is owned by hedge funds and other institutional investors.

DiaMedica Therapeutics Stock Performance

DiaMedica Therapeutics stock opened at $8.69 on Thursday. The firm’s fifty day moving average price is $7.28 and its 200-day moving average price is $6.74. The stock has a market cap of $468.65 million, a P/E ratio of -12.07 and a beta of 0.92. DiaMedica Therapeutics has a fifty-two week low of $5.24 and a fifty-two week high of $10.42.

DiaMedica Therapeutics (NASDAQ:DMAC) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.01. On average, analysts predict that DiaMedica Therapeutics will post -0.84 earnings per share for the current year.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for serious diseases affecting the kidneys and nervous system. The company’s research is centered on biological pathways that may support tissue protection and recovery in conditions with limited treatment options.

Its lead investigational product, DM199, is a recombinant form of human tissue kallikrein-1, an enzyme involved in the kallikrein-kinin system. DiaMedica has studied DM199 in acute ischemic stroke and kidney-related disorders, including severe acute kidney injury.